Profitability Metrics

Gross Margin
43.32%
Operating Margin
19.40%
Net Margin
14.80%

Efficiency Metrics

Revenue per Expense Ratio
1.24
R&D as % of Revenue
2.79%

Earnings Quality

EBITDA Margin
22.44%
Income Tax Rate
12.41%
EPS
6.1500000000

Balance Sheet Analysis

Current Ratio
1.26
Cash Ratio
0.43
Working Capital
$281.20M
Debt to Equity
1.53
Debt to Assets
46.74%
Equity Ratio
30.58%

Cash Flow Analysis

Operating Cash Flow Ratio
16.45%
Free Cash Flow Ratio
14.14%
CapEx to Revenue
2.31%
Dividends Paid
$158.70M
Stock Buybacks
$59.90M
Total Shareholder Returns
$218.60M
Cash Position Change
62.53%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 10.41%
  • Increased R&D investment by 36.78%

Detailed Growth Metrics

Core Performance

Revenue
11.58%
Net Income
17.99%
EPS
18.27%
Operating Income
20.80%

Operational Efficiency

R&D Expenses
36.78%
SG&A Expenses
17.61%
Operating Cash Flow
30.71%
Free Cash Flow
30.57%

Balance Sheet Health

Assets
8.03%
Debt
-3.80%
Book Value per Share
39.74%
Inventory
-8.46%

Shareholder Returns

Dividends per Share
10.41%
Shares Outstanding
-0.11%

Long Term Trends

3Y Revenue/Share
40.94%
5Y Revenue/Share
44.44%
3Y Dividend/Share
42.07%
5Y Dividend/Share
116.02%